Contemporary Treatment of Complement-Mediated Diseases
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".
Deadline for manuscript submissions: 16 October 2026 | Viewed by 166
Special Issue Editors
Interests: complement-mediated diseases; complement activation; kidney diseases; hemolytic uremic syndrome; kidney transplantation; antibody-mediated rejection
2. Department of Pediatrics, Zabok General Hospital and Croatian Veterans Hospital, Zabok, Croatia
Interests: complement-mediated diseases; complement activation; kidney diseases; hemolytic uremic syndrome
Special Issue Information
Dear Colleagues,
Complement-mediated diseases are increasingly recognized as a major driver of pathology across nephrology, hematology, transplantation, and immunology. Disorders such as atypical hemolytic uremic syndrome, C3 glomerulopathy, and complement-associated kidney allograft injury illustrate how dysregulated complement activation drives thrombotic microangiopathy, glomerular inflammation, and antibody-mediated rejection. Advances in molecular understanding and the rapid development of complement-targeted therapies have transformed the management of these complex and difficult-to-treat diseases. Globally, advances in molecular diagnostics, the availability of genetic testing, and the emergence of targeted complement inhibitors have reshaped therapeutic approaches and strategies. At the same time, important challenges remain, including uncertainty regarding polymorphism variant classifications, optimal treatment frequency and duration, and treatment discontinuation. There remains an unmet need for robust long-term safety and effectiveness data across diverse populations.
This Special Issue aims to present and disseminate the latest advances in the contemporary treatment of complement-mediated diseases. We consider contributions that address novel and emerging therapies, clinical trials, real-world evidence, treatment guidelines, and the implementation of complement-targeted therapies in routine clinical care.
Topics of interest for publication include, but are not limited to, the following:
- Hemolytic–uremic syndrome;
- Paroxysmal nocturnal hemoglobinuria (PNH);
- C3 glomerulopathy;
- Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN);
- Dense deposit disease (DDD);
- IgA nephropathy (IgAN);
- Membranous nephropathy (MN);
- ANCA-associated vasculitis with nephritis;
- Antibody-mediated rejection (humoral rejection) after kidney transplantation.
Dr. Daniel Turudić
Prof. Dr. Danko Milošević
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- complement-mediated diseases
- complement activation
- atypical hemolytic uremic syndrome
- C3 glomerulopathy
- thrombotic microangiopathy
- complement inhibitors
- kidney transplantation
- antibody-mediated rejection
- complement dysregulation
- genetic testing
- kidney failure
- dialysis
- kidney transplantation
- kidney allograft rejection
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
